These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 24997412

  • 1. The relationship between in vivo antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice.
    Kodama M, Yoshida R, Hasegawa T, Izawa M, Kitano M, Baba K, Noshi T, Seki T, Okazaki K, Tsuji M, Kanazu T, Kamimori H, Homma T, Kobayashi M, Sakoda Y, Kida H, Sato A, Yamano Y.
    Antiviral Res; 2014 Sep; 109():110-5. PubMed ID: 24997412
    [Abstract] [Full Text] [Related]

  • 2. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.
    Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS.
    Antiviral Res; 2011 Apr; 90(1):17-21. PubMed ID: 21316393
    [Abstract] [Full Text] [Related]

  • 3. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.
    Sato M, Ito M, Suzuki S, Sakuma H, Takeyama A, Oda S, Watanabe M, Hashimoto K, Miyazaki K, Kawasaki Y, Hosoya M.
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1643-9. PubMed ID: 25547357
    [Abstract] [Full Text] [Related]

  • 4. Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.
    Bentley ML, Hollistera AS, Hansenb AC, Smith JA, Cain JS.
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1105-11. PubMed ID: 25345428
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
    Saisho Y, Ishibashi T, Fukuyama H, Fukase H, Shimada J.
    Antivir Ther; 2017 Dec; 22(4):313-323. PubMed ID: 27805571
    [Abstract] [Full Text] [Related]

  • 6. Peramivir clearance in continuous renal replacement therapy.
    Thomas B, Hollister AS, Muczynski KA.
    Hemodial Int; 2010 Jul; 14(3):339-40. PubMed ID: 20491974
    [No Abstract] [Full Text] [Related]

  • 7. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
    Onishi M, Kitano M, Taniguchi K, Homma T, Kobayashi M, Yoshinaga T, Naito A, Sato A.
    Antiviral Res; 2015 May; 117():52-9. PubMed ID: 25752738
    [Abstract] [Full Text] [Related]

  • 8. Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.
    Bazan JA, Bauer KA, Hollister AS, Shidham G, Firstenberg MS, Reed EE, Mangino JE, Goff DA.
    Pharmacotherapy; 2010 Oct; 30(10):1016-20. PubMed ID: 20874039
    [Abstract] [Full Text] [Related]

  • 9. Peramivir for the treatment of influenza.
    Shetty AK, Peek LA.
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series.
    Cies JJ, Moore WS, Enache A, Chopra A.
    Pharmacotherapy; 2019 Nov; 39(11):1060-1065. PubMed ID: 31514223
    [Abstract] [Full Text] [Related]

  • 16. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.
    Arya V, Carter WW, Robertson SM.
    Clin Pharmacol Ther; 2010 Nov; 88(5):587-9. PubMed ID: 20959843
    [Abstract] [Full Text] [Related]

  • 17. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans.
    Atiee G, Lasseter K, Baughman S, McCullough A, Collis P, Hollister A, Hernandez J.
    J Clin Pharmacol; 2012 Sep; 52(9):1410-9. PubMed ID: 21960669
    [Abstract] [Full Text] [Related]

  • 18. Intravenous peramivir for treatment of influenza in hospitalized patients.
    Ison MG, Fraiz J, Heller B, Jauregui L, Mills G, O'Riordan W, O'Neil B, Playford EG, Rolf JD, Sada-Diaz E, Elder J, Collis P, Hernandez JE, Sheridan WP.
    Antivir Ther; 2014 Sep; 19(4):349-61. PubMed ID: 23985625
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of delayed treatment of China-made Peramivir with repeated intravenous injections in a mouse influenza model: from clinical experience to basal experiment.
    Li Z, Li R, Li J, Xie H, Hao Y, Du Q, Chen T, Li Y, Chen R, Yang Z, Zhong N.
    BMC Infect Dis; 2016 Jul 08; 16():325. PubMed ID: 27392915
    [Abstract] [Full Text] [Related]

  • 20. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
    Mancuso CE, Gabay MP, Steinke LM, Vanosdol SJ.
    Ann Pharmacother; 2010 Jul 08; 44(7-8):1240-9. PubMed ID: 20516360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.